Caring Brands, Inc. (NASDAQ:CABR) Sees Significant Decline in Short Interest

Caring Brands, Inc. (NASDAQ:CABR) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 2,863 shares, a decrease of 55.5% from the September 30th total of 6,427 shares. Based on an average daily trading volume, of 35,362 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Caring Brands in a report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Caring Brands Trading Up 4.1%

Shares of Caring Brands stock traded up $0.04 during trading on Friday, hitting $1.11. 33,492 shares of the stock were exchanged, compared to its average volume of 89,201. The company has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.15. The stock has a market capitalization of $11.66 million and a price-to-earnings ratio of -1.51. Caring Brands has a 1-year low of $0.71 and a 1-year high of $5.35.

Caring Brands (NASDAQ:CABR) last issued its earnings results on Thursday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Institutional Trading of Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Susquehanna International Group LLP bought a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 20,771 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned about 0.20% of Caring Brands at the end of the most recent quarter.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.